Abbott launches Xience Xpedition stent in Europe

Abbott is launching its new Xience Xpedition everolimus-eluting coronary stent system in Europe for the treatment of coronary artery disease this month.

The device has been granted CE Mark approval and features a new stent delivery system designed to optimise acute performance, particularly in challenging coronary anatomies.

It is available in one of the broadest size matrices on the European market and is backed by the robust clinical evidence of the Xience family of stents, which includes data from more than 45,000 patients across over 100 studies.

Xience Xpedition also has indications to treat patients with complex diseases such as diabetes, as well as an indication for a minimum duration of three months of dual anti-platelet therapy (DAPT).

The entire Xience line was approved for this DAPT specification in May 2012.

Dr Charles Simonton, divisional vice-president for medical affairs and chief medical officer at Abbott Vascular, said: "With Xience Xpedition, Abbott continues its commitment to advancing drug eluting stent technology to improve product performance and patient outcomes."